# OnCo record vorolanib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/vorolanib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "vorolanib" ;
  schema:name "Vorolanib"@en ;
  schema:alternateName "CM082"@en, "Fuwei"@en ;
  schema:description "Vorolanib is Betta Pharmaceuticals' oral VEGFR and PDGFR inhibitor, approved in China in 2023 with everolimus for advanced kidney cancer after a first kinase inhibitor has failed."@en ;
  schema:url <https://onco.cc/drugs/vorolanib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://en.wikipedia.org/wiki/Vorolanib>, <https://clinicaltrials.gov/search?intr=vorolanib> ;
  onco:status "approved" ;
  onco:tag "china", "nmpa-approved" ;
  onco:modality "Oral multi-target VEGFR and PDGFR tyrosine kinase inhibitor" ;
  onco:approval "CN 2023: Advanced renal cell carcinoma after a prior tyrosine kinase inhibitor, with everolimus (June 2023)" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/betta/> ;
  onco:trials <https://onco.cc/trials/nct07047001/>, <https://onco.cc/trials/nct04373369/>, <https://onco.cc/trials/nct06523049/> .